ADA 2017

In part 5, the conclusion of this Exclusive Interview, Dr. Swapnil N. Rajpathak talks with Diabetes in Control Publisher Steve Freed during the ADA 2017 Scientific Sessions in San Diego, CA about upcoming research studies on patient adherence.

In part 4 of this Exclusive Interview, Dr. Swapnil N. Rajpathak talks with Diabetes in Control Publisher Steve Freed during the ADA 2017 Scientific Sessions in San Diego, CA about his interest in the comparative analysis of various drug classes and their real-world implications.

Diabetes in Control speaks with top endocrinologists and other medical professionals to bring you the latest in diabetes news and research. This week, we have another exclusive interview from the ADA 2017 Scientific Sessions in San Diego, CA. Dr. Swapnil N. Rajpathak is the Executive Director of the Center for …

In this Exclusive Interview, Dr. Swapnil N. Rajpathak talks with Diabetes in Control Publisher Steve Freed during the ADA 2017 Scientific Sessions in San Diego, CA. Swapnil N. Rajpathak, MD, MPH, DrPH is Executive Director for the Center for Observational and Real World Evidence at Merck.  To view the …

In part 3 of this Exclusive Interview, Dr. Swapnil N Rajpathak talks with Diabetes in Control Publisher Steve Freed during the ADA 2017 Scientific Sessions in San Diego, CA about patient claims of hypoglycemia while on DPP4 treatment.

In part 2 of this Exclusive Interview, Dr. Swapnil N. Rajpathak talks with Diabetes in Control Publisher Steve Freed during the ADA 2017 Scientific Sessions in San Diego, CA about the ultimate savings in the use of DPP4s — reduced risk of hypoglycemia.

In part 1 of this Exclusive Interview, Dr. Swapnil N. Rajpathak talks with Diabetes in Control Publisher Steve Freed during the ADA 2017 Scientific Sessions in San Diego, CA about the contribution of the DPP4’s to the reduction of hypoglycemic risk.

Thomas Seck is Vice President of US Clinical Development and Medical Affairs Primary Care at Boehringer Ingelheim. Thomas earned his medical degree from the University of Mainz in Germany. He completed his residency and fellowship within the Department of Endocrinology and Metabolism, at the University of Heidelberg, Germany.

In this exclusive interview transcript, Thomas Seck discusses new data on the effect of Empagliflozin compared to standard of care for cardiovascular death, for hospitalization of heart failure, for overall mortality independent of changes in blood pressure, in HbA1C and in blood lipids.

In this Exclusive Interview, Dr. Thomas Seck talks with Diabetes in Control Publisher Steve Freed during the ADA 2017 Scientific Sessions in San Diego, CA about new data on the effects of Empagliflozin and how it compares to the standard of care in terms of cardiovascular death, overall mortality independent of changes in blood pressure, in HbA1C and in blood lipids.